Medication info
Janumet Tablet 50/1000 mg

Janumet Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›56.7mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
HLB Therapeutics Co., Ltd.
Appearance
Oval tablet with a dark red film coating
Packaging
56 tablets/box [14 tablets/PTP×4], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202204565 · Approved 2022.12.21 · Insurance code 647304410

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes medication who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this product 50/500 mg twice daily; this may be increased to 1 tablet of this product 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin must not be switched to this product (see Precautions for Use, 2. Patients Who Must Not Use This Product). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this product may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this product. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this product should not be initiated, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product must be discontinued immediately. Patients with hepatic impairment This product must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Product).

Ingredients

Manufacturer
HLB Therapeutics Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes by supporting dietary and exercise regimens. The combination of sitagliptin and metformin effectively improves blood glucose levels. Using this medication allows for smoother management of blood sugar, helping to prevent diabetes-related complications. Therefore, it is used to enhance blood glucose control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this product should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This product is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this product should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes medication who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose is 1 tablet of this product 50/500 mg twice daily; this may be increased to 1 tablet of this product 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin must not be switched to this product (see Precautions for Use, 2. Patients Who Must Not Use This Product). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this product is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from combination therapy with sitagliptin and metformin to this product may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this product is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this product. Any change in the treatment regimen for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This product may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this product should not be initiated, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this product must be discontinued immediately. Patients with hepatic impairment This product must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Product).

Precautions

This medication contains sitagliptin and metformin, and is used in diabetes treatment. While taking this medication, serious allergic reactions may occur; therefore, if symptoms such as rashes, hives, or difficulty in breathing appear, stop taking the medication immediately and consult a doctor. Acute pancreatitis may occur, so inform healthcare providers immediately if severe abdominal pain or vomiting occurs. Patients with severely impaired kidney function or at risk for acute renal failure should not take this medication and should regularly have their kidney function tested. Avoid taking this medication if you have severe infections, dehydration, heart disease, heart failure, or acute myocardial infarction. When undergoing tests with iodinated contrast media, this medication should be temporarily discontinued and should only be resumed after confirming normal kidney function post-exam. Pregnant or potentially pregnant women, as well as breastfeeding women, should not take this medication. This medication may cause hypoglycemia, so particular caution is needed when skipping meals, eating irregularly, exercising vigorously, or taking it with other hypoglycemic agents. Gastrointestinal disturbances, diarrhea, nausea, vomiting, headache, etc., may occur and should be discussed with a doctor if severe. Alcohol may increase the risk of side effects with this medication, so alcoholic beverages should be avoided while taking it. In cases where surgery is planned, the medication should be stopped 48 hours prior, and should only be resumed after verifying normal kidney function post-surgery. Elderly patients may have an increased risk of kidney function decrease; thus, dosage adjustments and regular kidney function tests are needed. During the course of treatment, regular checks of blood glucose, kidney function, and blood tests should be conducted to monitor for abnormalities. In case of overdose, visit a medical institution immediately for appropriate treatment, and blood dialysis may be necessary.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 21 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe joint pain with disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • acute kidney failure
  • decreased appetite
  • itching
  • dermatitis
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture exposure, and is safe to store at room temperature between 1 and 30 degrees Celsius. Therefore, avoid direct sunlight and do not leave it in excessively hot or cold places.

Appearance and packaging

Appearance

Oval tablet with a dark red film coating

Package unit

56 tablets/box [14 tablets/PTP×4], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.